Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2014

View Archived Issues

Pfizer researchers design nicotine vaccines with higher avidity

Gilead's GS-5806 effective in phase IIa RSV trial

TxCell's Col-Treg receives Advanced Therapy Medicinal Product designation

Extended recombinant PTH treatment demonstrates good efficacy for hypoparathyroidism

Novel uPAR-derived peptide tested for ocular angiogenesis-related diseases

Isis Pharmaceuticals reports data for ISIS-FXI-Rx in prevention of venous thrombosis

Dabigatran etexilate antidote progresses into next stage of clinical investigation

Novel non-retinoid therapeutic for AMD significantly reduces RBP4 plasma levels

H3 Biomedicine and Selvita achieve milestone in oncology collaboration

Bifunctional shRNA shows efficacy for the treatment of Ewing's sarcoma

Novel patent describes Wnt signaling inhibitors

Imatinib receives FDA orphan drug designation for PML

Nerviano Medical Sciences reports discovery of new PARP-1 inhibitors

Volitinib enters phase II trial in renal cell carcinoma

Toray Industries discloses nAChR alpha-7 agonists

Emory University synthesizes novel 7,8-dihydroxyflavone prodrugs

NeurOp selects development candidate for subarachnoid hemorrhage

Forxiga launched in Japan for the treatment of type 2 diabetes

Taisho Pharmaceutical launches Lusefi in Japan

Astellas launches Xtandi in Japan for prostate cancer

FDA approves dalbavancin for bacterial skin and skin structure infections

Vectibix plus FOLFOX approved in U.S. for wild-type KRAS metastatic colorectal cancer

GSK submits regulatory submission for umeclidinium monotherapy in Japan

Lonsurf combination tablet scheduled for launch in Japan

CHMP issues positive opinion for Translarna for nonsense mutation DMD

Dainippon proposes changes to prepare for global development of business

EMA committee recommends approval of obinutuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...